| Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma (NCT07769658) | The First Affiliated Hospital of Zhengzhou University | 2026-09-01 |
| A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation. (NCT07774143) | The First Affiliated Hospital of Zhengzhou University | 2026-06-20 |
| Pro-urokinase for Extended-Window Posterior Circulation Stroke (NCT07617870) | The First Affiliated Hospital of Zhengzhou University | 2026-06-01 |
| Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch (NCT07540416) | The First Affiliated Hospital of Zhengzhou University | 2026-05-01 |
| Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality (NCT07501975) | The First Affiliated Hospital of Zhengzhou University | 2026-04-01 |
| A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT07446335) | The First Affiliated Hospital of Zhengzhou University | 2026-04-01 |
| Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate (NCT07501962) | The First Affiliated Hospital of Zhengzhou University | 2026-04-01 |
| IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer (NCT07361991) | The First Affiliated Hospital of Zhengzhou University | 2026-03-01 |
| The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemiplegic Patients After Stroke (NCT07454954) | The First Affiliated Hospital of Zhengzhou University | 2026-03-01 |
| Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome (NCT05114941) | The First Affiliated Hospital of Zhengzhou University | 2026-01-01 |
| Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer (NCT07314619) | The First Affiliated Hospital of Zhengzhou University | 2025-12-30 |
| A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (NCT07128693) | The First Affiliated Hospital of Zhengzhou University | 2025-09-01 |
| Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer (NCT07085273) | The First Affiliated Hospital of Zhengzhou University | 2025-08-15 |
| A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer (NCT07770113) | The First Affiliated Hospital of Zhengzhou University | 2025-06-30 |
| PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer (NCT07294664) | The First Affiliated Hospital of Zhengzhou University | 2025-06-15 |
| Spatiotemporal Dynamics and Prognostic Value of the 18F-FDG PET Neuro-Metabolic Network (NCT07203495) | The First Affiliated Hospital of Zhengzhou University | 2025-06-01 |
| Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC (NCT06896422) | The First Affiliated Hospital of Zhengzhou University | 2025-06-01 |
| NR vs. Vitamin E in Enhancing Fertility (NCT06950736) | The First Affiliated Hospital of Zhengzhou University | 2025-05-05 |
| Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions (NCT07463664) | The First Affiliated Hospital of Zhengzhou University | 2025-04-28 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL (NCT06559345) | The First Affiliated Hospital of Zhengzhou University | 2025-03-17 |
| Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer (NCT07104149) | The First Affiliated Hospital of Zhengzhou University | 2025-03-10 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL (NCT06557161) | The First Affiliated Hospital of Zhengzhou University | 2025-03-01 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL (NCT06564493) | The First Affiliated Hospital of Zhengzhou University | 2025-03-01 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL (NCT06564545) | The First Affiliated Hospital of Zhengzhou University | 2025-03-01 |
| Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer (NCT06760520) | The First Affiliated Hospital of Zhengzhou University | 2025-01-20 |
| Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy (NCT06746961) | The First Affiliated Hospital of Zhengzhou University | 2025-01-01 |
| A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk (NCT06930573) | The First Affiliated Hospital of Zhengzhou University | 2024-12-04 |
| Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma (NCT06901622) | The First Affiliated Hospital of Zhengzhou University | 2024-11-08 |
| A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma (NCT07599371) | The First Affiliated Hospital of Zhengzhou University | 2024-10-10 |
| Energy CT in Imaging and Diagnosis of Gastric Cancer (NCT06869694) | The First Affiliated Hospital of Zhengzhou University | 2024-09-01 |
| Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer (NCT07016724) | The First Affiliated Hospital of Zhengzhou University | 2024-08-15 |
| Effects of ITBS Combined with NMES on Dysphagia After Stroke (NCT06464835) | The First Affiliated Hospital of Zhengzhou University | 2024-08-03 |
| Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC (NCT06439550) | The First Affiliated Hospital of Zhengzhou University | 2024-07-15 |
| RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer (NCT06492317) | The First Affiliated Hospital of Zhengzhou University | 2024-07-06 |
| Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer (NCT06697782) | The First Affiliated Hospital of Zhengzhou University | 2024-07-01 |
| Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project. (NCT07169656) | The First Affiliated Hospital of Zhengzhou University | 2024-06-03 |
| Comparison of the Integrated Posterior-Anterior-Lateral Approach and the Posterior Approach in Robotic Radical Prostatectomy (NCT07305142) | The First Affiliated Hospital of Zhengzhou University | 2024-05-16 |
| Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC) (NCT06930586) | The First Affiliated Hospital of Zhengzhou University | 2024-03-01 |
| Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain (NCT06747728) | The First Affiliated Hospital of Zhengzhou University | 2024-03-01 |
| Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer (NCT06341530) | The First Affiliated Hospital of Zhengzhou University | 2024-01-31 |
| Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer (NCT06231017) | The First Affiliated Hospital of Zhengzhou University | 2024-01-19 |
| Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage (NCT06194981) | The First Affiliated Hospital of Zhengzhou University | 2024-01-11 |
| Tumor Microenvironmental Collagen Signature to Predict Thyroid Cancer Superior Mediastinal Lymph Node Metastasis (NCT06791174) | The First Affiliated Hospital of Zhengzhou University | 2024-01-01 |
| Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study (NCT06194968) | The First Affiliated Hospital of Zhengzhou University | 2023-12-30 |
| The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19 (NCT06349655) | The First Affiliated Hospital of Zhengzhou University | 2023-12-05 |
| IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) (NCT06078657) | The First Affiliated Hospital of Zhengzhou University | 2023-10-01 |
| Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) (NCT05896787) | The First Affiliated Hospital of Zhengzhou University | 2023-08-01 |
| Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer (NCT05841134) | The First Affiliated Hospital of Zhengzhou University | 2023-06-01 |
| Cortical Function Changes During Swallowing in Patients With Dysphagia in Lateral Medullary Syndrome (NCT06208020) | The First Affiliated Hospital of Zhengzhou University | 2023-05-31 |
| Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer (NCT05812430) | The First Affiliated Hospital of Zhengzhou University | 2023-04-10 |
| Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma (NCT06718205) | The First Affiliated Hospital of Zhengzhou University | 2023-03-08 |
| Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC (NCT05738434) | The First Affiliated Hospital of Zhengzhou University | 2023-03-02 |
| Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade (NCT05265962) | The First Affiliated Hospital of Zhengzhou University | 2022-12-01 |
| Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter in Patients With Medullary Infarction (NCT06196606) | The First Affiliated Hospital of Zhengzhou University | 2022-11-11 |
| Effect of Botulinum Toxin Injection Guided by Ultrasound Combined With Balloon Localization on Cricopharyngeal Achalasia (NCT06213662) | The First Affiliated Hospital of Zhengzhou University | 2022-11-01 |
| Mindfulness Yoga and Sexual Functioning (NCT05461534) | The First Affiliated Hospital of Zhengzhou University | 2022-08-01 |
| A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion (NCT05330065) | The First Affiliated Hospital of Zhengzhou University | 2022-08-01 |
| Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma (NCT07619937) | The First Affiliated Hospital of Zhengzhou University | 2022-07-22 |
| An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer (NCT05186545) | The First Affiliated Hospital of Zhengzhou University | 2022-07-01 |
| Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy (NCT05350917) | The First Affiliated Hospital of Zhengzhou University | 2022-06-20 |
| MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC (NCT05286957) | The First Affiliated Hospital of Zhengzhou University | 2022-06-20 |
| Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer (NCT05364489) | The First Affiliated Hospital of Zhengzhou University | 2022-06-15 |
| Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study (NCT05381636) | The First Affiliated Hospital of Zhengzhou University | 2022-06-01 |
| A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia (NCT05350956) | The First Affiliated Hospital of Zhengzhou University | 2022-06-01 |
| Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT05024812) | The First Affiliated Hospital of Zhengzhou University | 2022-06-01 |
| A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer (NCT05241899) | The First Affiliated Hospital of Zhengzhou University | 2022-05-07 |
| Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer (NCT05349045) | The First Affiliated Hospital of Zhengzhou University | 2022-05-05 |
| Genetic Research on High Myopic Individuals in Northern China (NCT06204211) | The First Affiliated Hospital of Zhengzhou University | 2022-05-01 |
| Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma (NCT05189184) | The First Affiliated Hospital of Zhengzhou University | 2022-03-30 |
| Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) (NCT05038813) | The First Affiliated Hospital of Zhengzhou University | 2022-03-14 |
| AK105 Combined With Anlotinib in Patients With Cervical Cancer (NCT05137171) | The First Affiliated Hospital of Zhengzhou University | 2022-03-01 |
| A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI. (NCT05231850) | The First Affiliated Hospital of Zhengzhou University | 2022-03-01 |
| A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC (NCT05182944) | The First Affiliated Hospital of Zhengzhou University | 2022-01-15 |
| Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer (NCT04654403) | The First Affiliated Hospital of Zhengzhou University | 2022-01-01 |
| Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma (NCT04888403) | The First Affiliated Hospital of Zhengzhou University | 2021-12-31 |
| Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade (NCT04984018) | The First Affiliated Hospital of Zhengzhou University | 2021-12-01 |
| Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC (NCT04819971) | The First Affiliated Hospital of Zhengzhou University | 2021-12-01 |
| A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC (NCT04514835) | The First Affiliated Hospital of Zhengzhou University | 2021-12-01 |
| Tislelizumab in Addition to BACE in Patients with NSCLC (NCT05058560) | The First Affiliated Hospital of Zhengzhou University | 2021-12-01 |
| A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma (NCT04533490) | The First Affiliated Hospital of Zhengzhou University | 2021-10-01 |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (NCT03766178) | The First Affiliated Hospital of Zhengzhou University | 2021-09-01 |
| Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B (NCT04850950) | The First Affiliated Hospital of Zhengzhou University | 2021-04-26 |
| Thrombolysis of Urokinase for Minor Stroke (NCT04420351) | The First Affiliated Hospital of Zhengzhou University | 2020-10-04 |
| A Clinical Study on Ozone Autohemotherapy for the Treatment of Acute Ischemic Stroke (NCT06525792) | The First Affiliated Hospital of Zhengzhou University | 2020-08-01 |
| Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC (NCT04611373) | The First Affiliated Hospital of Zhengzhou University | 2020-05-01 |
| The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC (NCT03917966) | The First Affiliated Hospital of Zhengzhou University | 2020-04-07 |
| A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (NCT03736863) | The First Affiliated Hospital of Zhengzhou University | 2019-12-05 |
| A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC (NCT03817658) | The First Affiliated Hospital of Zhengzhou University | 2019-10-01 |
| Novel Treatment of Advanced Hepatocellular Carcinoma (NCT03950518) | The First Affiliated Hospital of Zhengzhou University | 2019-04-10 |
| Treatment of Advanced Intrahepatic Cholangiocarcinoma (NCT03940378) | The First Affiliated Hospital of Zhengzhou University | 2019-02-01 |
| Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma (NCT03387904) | The First Affiliated Hospital of Zhengzhou University | 2019-01-13 |
| Glioma Patients Registry Based on Radiological, Histopathological and Genetic Analysis (NCT04220424) | The First Affiliated Hospital of Zhengzhou University | 2018-11-01 |
| Drug-coated Balloon Angioplasty for Patients With Symptomatic Vertebral Artery Stenosis (NCT03504657) | The First Affiliated Hospital of Zhengzhou University | 2018-05-03 |
| A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma (NCT03521219) | The First Affiliated Hospital of Zhengzhou University | 2018-02-07 |
| Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI (NCT03406832) | The First Affiliated Hospital of Zhengzhou University | 2018-01-08 |
| Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI (NCT03406819) | The First Affiliated Hospital of Zhengzhou University | 2018-01-07 |
| Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas (NCT04216550) | The First Affiliated Hospital of Zhengzhou University | 2018-01-01 |
| The Effect of Vitamin D on in Vitro Fertilization Outcome (NCT02361827) | The First Affiliated Hospital of Zhengzhou University | 2018-01-01 |
| Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas (NCT04216537) | The First Affiliated Hospital of Zhengzhou University | 2018-01-01 |
| Botulinum Toxin for Trigeminal Neuralgia (NCT03331913) | The First Affiliated Hospital of Zhengzhou University | 2017-11-07 |